Search results

Selected filters:

North America

Article type

Topic

Sector

Jurisdictions

3,204 results found for your search

Sort options
11 December 2018

SEP owners find more reason to cheer latest DOJ proposal on injunctions

Despite proposed new statement, question remains over the extent to which Makan Delrahim’s FRAND policy will find approval with the man likely to be the next Attorney General

11 December 2018

The patents that earned Qualcomm an iPhone injunction in China

IAM uncovers the patents-in-suit, runs down the two sides’ validity wins and losses so far, and provides much more analysis of yesterday's shock preliminary injunction in the Intermediate People's Court of Fuzhou

10 December 2018

Seiko Epson makes more big disposals

Former collaboration partner E Ink picks up nearly 800 patents; assignments reveal almost as many rights sold to OLED startup last year

07 December 2018

“No barriers, no fees”: China Mobile announces 5G royalty policy

World’s largest mobile operator pledges not to collect licence fees on 5G contributions which reports say have generated nearly 1,000 patent applications

07 December 2018

Boston Scientific enhances its patent portfolio with BTG acquisition

An in-depth analysis shows that the American medical device manufacturer may not gain much in terms of quantity from its $4 billion purchase, but that the British healthcare company’s IP assets will boost its peripheral interventional offerings

06 December 2018

China to blacklist "serious" patent infringers

Days after announced trade truce, China’s government explains ‘social credit score’ consequences for IP infringers first floated three years ago. Penalties range from borrowing restrictions to air travel bans.

06 December 2018

Former Google dealmaker becomes latest senior player to exit tech giant

John LaBarre's move to a biotech start-up follows previous departures of Allen Lo and Jeremiah Chan to Facebook, and is further evidence of the narrowing IP strategy gap between high-tech and the life sciences  

05 December 2018

SUCCESS Act extends USPTO's fee-setting authority

The SUCCESS Act reads as a feel-good piece of legislation that acknowledges the growing role of underrepresented classes in the innovation ecosystem. However, it maintains the USPTO's controversial fee-setting authority.

04 December 2018

New lawsuits against AT&T, Sprint and Verizon suggest ETRI is doubling down on US monetisation strategy

After setback in Huawei suit, latest court cases show the state-funded Korean research institute is behind massive licensing programme

30 November 2018

A director’s guide to modernising IP governance frameworks

Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.

30 November 2018

How a Chinese court would have answered the three questions in the Unwired Planet appeal

Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions 

30 November 2018

Time is running out to nominate the world’s leading IP strategists

There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.

30 November 2018

Doing intellectual property the Dolby Labs way

For over half a century Dolby Labs has worked hard to ensure that the company’s IP strategy is always aligned with its overall business goals. Its success in doing this teaches valuable lessons.

30 November 2018

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.

30 November 2018

US pharma patents are under greater threat than ever before

Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.